Biotech · Private company
Ray Therapeutics, Inc.
Track this companyFree. Adds Ray Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- RTx-015Phase 3 · Retinitis Pigmentosa (RP)ClinicalTrials.gov · fetched Nov 12, 2026
- Sham ControlPhase 3 · Retinitis Pigmentosa (RP)ClinicalTrials.gov · fetched Nov 12, 2026
- RTx-021Phase 2 · Stargardt DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- RTx-015Phase 1 · Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)PHASE2_PHASE3 · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07901751 · fetched Nov 12, 2026
- Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)RECRUITING · started Feb 19, 2026ClinicalTrials.gov NCT07502664 · fetched Nov 12, 2026
- Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt DiseasePHASE1_PHASE2 · RECRUITING · started Jan 28, 2026ClinicalTrials.gov NCT07439887 · fetched Nov 12, 2026
- Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 27, 2024ClinicalTrials.gov NCT06460844 · fetched Nov 12, 2026
- Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal DegenerationRECRUITING · started Apr 5, 2024ClinicalTrials.gov NCT06375239 · fetched Nov 12, 2026